Fresenius Medical Care AG (FMS) Form 6-K — May 26, 2026
Fresenius Medical Care announced a new share buyback program with a total volume of approximately EUR 1 billion, to be executed in tranches over 12 months starting in the near future. This follows the successful completion of a previous EUR 1 billion buyback program in under one year, during which 24.8 million shares (8.5% of share capital) were repurchased and subsequently cancelled. At its Annual General Meeting, shareholders approved a dividend of EUR 1.49 per share for fiscal year 2025, up from EUR 1.44 in 2024, and granted the Management Board a new five-year authorization to acquire and use treasury shares.
Key figures
- Dividend
- EUR 1.49
- Buyback Volume
- EUR 1,000,000,000
- Operating Margin
- 11.3%
- Net Leverage Ratio
- 2.5x
- Shares Repurchased
- 24,848,819
- Organic Revenue Growth
- 8%
- Dividend Payout Ratio
- 30-40%
- Previous Buyback Volume
- EUR 1,000,000,000
- Share Capital Reduction
- EUR 24,848,819
- Treasury Shares Cancelled
- 24,848,819
- Post Cancellation Share Capital
- EUR 268,564,630
- Post Cancellation Shares Outstanding
- 268,564,630
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.